NCT06577441
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 176 versions: 30 with changes below, 20 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 149 → 152 locations
- Minor Study sites: 150 to 151
- Minor Study sites: 149 to 150
- Minor Trial sites expanded: 146 → 149 locations
- Minor Study sites: 147 to 148
Show 12 earlier versionsHide 12 earlier versions
- Minor Study sites: 146 to 147
- Minor Study sites: 145 to 146
- Minor Study sites: 144 to 145
- Minor Site details revised at 2 of 144 sites
- Minor Site details revised at 2 of 144 sites
- Notable Eligibility criteria expanded, about 33 words
- Secondary endpoints: details revised at 5 of 10 entries
- Study description revised
- Site details revised at 16 of 144 sites
- Minor Study sites: 143 to 144v165
- Minor Site details revised at 2 of 143 sitesv164
- Minor Site contacts updated at 1 of 143 sitesv163
- Minor Study sites: 142 to 143v162
- Minor Study sites: 143 to 142v160
- Notable Eligibility criteria expanded, about 10 words
- Study sites revised (143)
- Minor Trial sites expanded: 140 → 143 locationsv158
- Minor Site details revised at 3 of 140 sitesv157
- Minor Site details revised at 4 of 140 sitesv156
- Minor Site details revised at 1 of 140 sitesv155
- Minor Study sites: 139 to 140v153
- Minor Site details revised at 1 of 139 sitesv152
- Minor Study sites: 138 to 139v151
- Minor Study sites: 137 to 138v142
- Minor Site details revised at 2 of 137 sitesv141
- Minor Study sites: 136 to 137v140
- Minor Site details revised at 1 of 136 sitesv130
- Minor Study sites: 135 to 136v129
- Minor Site details revised at 1 of 135 sitesv128
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Drugs: Decitabine and Cedazuridine, Enasidenib
Sites
152 sites in 2 countries
United States 150, Puerto Rico 2